Gliomas are the most common primary brain tumors with GBM as the most common type and the most aggressive with median survival of about a year. The GBMs are now divided into 3 or 4 subgroups based on molecular signaling pathways and transcription profiles (Brennan et al, PLOS One 2009). We now have very accurate mouse models of the GBM subgroups and the most widely used is the PDGF-driven model of the proneural subgroup (Dai et al. Genes and Dev 2001). This model has provided us with a great deal of information about the biology of these tumors, especially about the tumor microenvironment around the perivascular niche (Charles et al. Cell Stem Cell 2009). These tumors show a collection of cells around the blood vessels that are not tumor cell-derived but contribute to the biology of the tumor in many ways. These cells include astrocytes, inflammatory cells and smooth muscle cells and provide a haven for tumor cells with stem cell character (Bleau et al. Cell Stem Cell 2009) and provide resistance to therapy (Hambardzumyan et al, Genes and Dev 2008). In this grant we will use novel technology to design mice that will allow us to obtain the translating mRNAs for these various cell types in vivo in these tumors. We will use this technology to measure the expression differences induced by standard of care therapy in an attempt to understand how the various cell types of the perivascular niche contribute to resistance to therapy. Our observafions in the mice will then be compared with human GBM samples of various subtypes to understand the role of these stromal cells of the glioma microenvironment.
Aim 1. In mouse models of proneural GBMs we will determine which cells of the perivascular stroma produce the gene products that drive the resistance phenotype in human GBM.
Aim 2. In human proneural GBM surgical samples we will verify in which perivascular cell types these genes are produced.
Aim 3. In mouse models of proneural GBMs we will determine if expression of these genes in their respective cell types is regulated by aggressiveness of the tumor cells or if it responds to treatment with radiation and temozolomide over time.
Aim 4. In mouse models of proneural GBMs we will knock down these genes in the appropriate perivascular cell type to determine if any of them are causally related to therapeufic resistance.
Aim 5. In this aim we will extend the above aims to NFI/mesenchymal and EGFR/classical GBMs.
| Ozawa, Tatsuya; Arora, Sonali; Szulzewsky, Frank et al. (2018) A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-?B. Cell Rep 23:3787-3797 |
| Itkin, Tomer; Gómez-Salinero, Jesús María; Rafii, Shahin (2017) Open the gates: vascular neurocrine signaling mobilizes hematopoietic stem and progenitor cells. J Clin Invest 127:4231-4234 |
| Guo, Peipei; Poulos, Michael G; Palikuqi, Brisa et al. (2017) Endothelial jagged-2 sustains hematopoietic stem and progenitor reconstitution after myelosuppression. J Clin Invest 127:4242-4256 |
| Park, Young Bong; Hohl, Marcel; Padjasek, Micha? et al. (2017) Eukaryotic Rad50 functions as a rod-shaped dimer. Nat Struct Mol Biol 24:248-257 |
| Lis, Raphael; Karrasch, Charles C; Poulos, Michael G et al. (2017) Conversion of adult endothelium to immunocompetent haematopoietic stem cells. Nature 545:439-445 |
| Shido, Koji; Chavez, Deebly; Cao, Zhongwei et al. (2017) Platelets prime hematopoietic and vascular niche to drive angiocrine-mediated liver regeneration. Signal Transduct Target Ther 2: |
| Boire, Adrienne; Zou, Yilong; Shieh, Jason et al. (2017) Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis. Cell 168:1101-1113.e13 |
| Kim, Jun Hyun; Grosbart, Malgorzata; Anand, Roopesh et al. (2017) The Mre11-Nbs1 Interface Is Essential for Viability and Tumor Suppression. Cell Rep 18:496-507 |
| Amankulor, Nduka M; Kim, Youngmi; Arora, Sonali et al. (2017) Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev 31:774-786 |
| Massagué, Joan; Obenauf, Anna C (2016) Metastatic colonization by circulating tumour cells. Nature 529:298-306 |
Showing the most recent 10 out of 41 publications
